Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosis.

MLA

Hammoudeh, Mohammed, et al. “Safety of Tumor Necrosis Factor Inhibitors Use for Rheumatoid Arthritis and Ankylosing Spondylitis in Africa, the Middle East, and Asia: Focus on Severe Infections and Tuberculosis.” Clinical Rheumatology, vol. 32, no. 3, Mar. 2013, pp. 293–300. EBSCOhost, https://doi.org/10.1007/s10067-012-2137-7.

APA

Hammoudeh, M., Alarfaj, A., Chen, D.-Y., Djoudi, H., Youseif, E., & Zhu, J. (2013). Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosis. Clinical Rheumatology, 32(3), 293–300. https://doi.org/10.1007/s10067-012-2137-7

Chicago

Hammoudeh, Mohammed, Abdurhman Alarfaj, Der-Yuan Chen, Hachemi Djoudi, Ehab Youseif, and Jian Zhu. 2013. “Safety of Tumor Necrosis Factor Inhibitors Use for Rheumatoid Arthritis and Ankylosing Spondylitis in Africa, the Middle East, and Asia: Focus on Severe Infections and Tuberculosis.” Clinical Rheumatology 32 (3): 293–300. doi:10.1007/s10067-012-2137-7.